Date: 2012-03-21
Type of information: Collaboration agreement
Compound:
Company: Stevenage BioScience Catalyst (UK) Kurma Life Sciences Partners (France)
Therapeutic area:
Type agreement: collaboration
Action mechanism:
Disease:
Details: * On March 21 2012, Stevenage Bioscience Catalyst (SBC), the UK’s first open innovation bioscience campus, and Kurma Life Sciences Partners (Kurma), have announced that they have signed a memorandum of understanding to enable them to work together on establishing and funding new life sciences companies. It is anticipated that funding will also be available for small proof-of-concept projects.
One of SBC\'s main objectives is to play a part in the rejuvenation of the UK biotechnology sector, and the collaboration with Kurma will facilitate this. Through the Kurma BioFund 1, the latter exploits intellectual property from the Instituts Pasteur and Curie, and other academic centres of excellence. Under the terms of the agreement, the parties will work together and independently on sourcing investments based on innovative science, from both academia and the pharmaceutical industry.
SBC\'s strong relationships with its stakeholders, the Wellcome Trust, GlaxoSmithKline and the UK Government, are expected to facilitate this. In the first instance, it is anticipated that fledgling companies will be incubated at Stevenage Bioscience Catalyst.
Financial terms:
Latest news:
